In the article, Nazari examines how direct-to-patient distribution has evolved into a core capability that enables manufacturers to expand patient access, control the patient experience, and capture valuable real-world data on adherence and outcomes while reducing dependence on traditional intermediaries.

‍

The piece highlights a critical challenge facing the industry as more companies launch direct-to-patient programs. Many manufacturers are assembling disconnected technology solutions rather than building integrated platforms, resulting in patient drop-off rates as high as 30-40%, inflated operating costs, and limited visibility into the patient journey.

‍

Nazari outlines why purpose-built, end-to-end integrated technology platforms provide the control, visibility, and scalability needed to succeed in this new landscape. The article explores how unified infrastructure enables real-time data synchronization across prescribers, payers, pharmacies, and patients while balancing automation with clinical oversight to maintain compliance and patient safety.

‍

The feature also addresses how transparency builds both patient trust and brand equity, with advanced analytics turning real-time visibility into strategic intelligence that can inform pricing decisions, identify where patients disengage, and continuously measure ROI.